Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human ARID1A Antibodies:
anti-Mouse (Murine) ARID1A Antibodies:
anti-Rat (Rattus) ARID1A Antibodies:
Go to our pre-filtered search.
Human Polyclonal ARID1A Primary Antibody for ICC, IF - ABIN4281563
Bolander, Agnarsdóttir, Strömberg, Ponten, Hesselius, Uhlen, Bergqvist: The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas. in Cancer genomics & proteomics 2009
Show all 21 Pubmed References
Human Polyclonal ARID1A Primary Antibody for WB - ABIN188644
Wurster, Precht, Pazin: NF-κB and BRG1 bind a distal regulatory element in the IL-3/GM-CSF locus. in Molecular immunology 2011
these data suggest that the combined treatment with PI3K (show PIK3CA Antibodies) inhibitor BKM120 and PARP (show COL11A2 Antibodies) inhibitor olaparib may be a promising therapeutic regimen for the treatment of gastric cancer, and ARID1A deficiency could serve as a potential predictive therapeutic biomarker.
Although Genome-Wide Association studies have not been carried out in the field of alcohol-related hepatocellular carcinoma (HCC (show FAM126A Antibodies)), common single nucleotide polymorphisms conferring a small increase in the risk of liver cancer risk have been identified. Specific patterns of gene mutations including CTNNB1 (show CTNNB1 Antibodies), TERT (show TERT Antibodies), ARID1A and SMARCA2 (show SMARCA2 Antibodies) exist in alcohol-related HCC (show FAM126A Antibodies). [review]
Sgk1 (show SGK1 Antibodies) stimulated OAT3 (show SLC22A8 Antibodies) transport activity by interfering with the inhibitory effect of Nedd4-2 (show NEDD4L Antibodies) on the transporter. This study provides important insights into how OAT3 (show SLC22A8 Antibodies)-mediated drug elimination is regulated in vivo.
The authors find that ARID1A has a dominant role in maintaining chromatin accessibility at enhancers, while the contribution of ARID1B (show ARID1B Antibodies) is evident only in the context of ARID1A mutation.
ARID1A and human epidermal growth factor receptor (show EGFR Antibodies)-2 (Her-2 (show ERBB2 Antibodies)) status were found to be independent prognostic factors of both overall survival (OS) and disease free survival (DFS (show FST Antibodies)).
ARID1A expression loss was associated with poor overall survival in Asians with gastric cancer. [meta-analysis]
the significant correlation was achieved between the negative ARID1A expression and the FIGO stage of endometrium-related gynecological cancers, but not the other characteristics.
This metaanalysis indicated that Gastric Cancer or Colorectal Cancer with ARID1A alteration might be a marker of poor prognosis. The ARID1A alteration of Gastric Cancer may result from different epigenetic factors.
Low ARID1A expression is associated with clear cell and endometrioid carcinoma of the ovary and the endometrium.
Loss of PTEN and ARID1A expression is highly specific for malignancy in effusion pathology
ARID1A regulates expression of SOX9, activation of the mTOR pathway, and differentiation of pancreatic ductal cells. ARID1A inhibits formation of pancreatic ductal adenocarcinomas from intraductal papillary mucinous neoplasms in mice with pancreatic expression of activated KRAS and is down-regulated in IPMN and PDAC tissues from patients.
Our results identified PIK3IP1 (show PIK3IP1 Antibodies) as a novel target of ARID1A and PGR (show PGR Antibodies) in the murine uterus.
Mice with liver-specific homozygous or heterozygous Arid1a loss were resistant to tumor initiation while ARID1A overexpression accelerated initiation.
Loss of HDAC (show HDAC3 Antibodies)-mediated repression and gain of NF-kappaB (show NFKB1 Antibodies) activation underlie cytokine induction in ARID1A- and PIK3CA (show PIK3CA Antibodies)-mutation-driven ovarian cancer.
ARID1A mutation inactivates the apoptosis-promoting function of p53 (show TP53 Antibodies) by upregulating HDAC6 (show HDAC6 Antibodies), indicating that pharmacological inhibition of HDAC6 (show HDAC6 Antibodies) is a therapeutic strategy for ARID1A-mutated cancers.
ARID1A normally targets SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) complexes to enhancers.
Consistent with the latter, Arid1a reexpression in tumor cells led to increased p21 (Cdkn1a (show CDKN1A Antibodies)) expression and dramatic accumulation of cells in G2 phase of the cell cycle. These results also indicate a potential opportunity for therapeutic intervention in ARID1A-deficient human breast cancer subtypes that retain one intact copy of the gene and also maintain wild-type TRP53 (show TP53 Antibodies) activity
The Arid1a loss reprograms chromatin to restrict promoter access by transcription factors such as C/ebpalpha (show CEBPA Antibodies), which enforces differentiation, and E2F4 (show E2F4 Antibodies), which suppresses cell-cycle re-entry.
This study provides an alternative mechanism by which Arid1a deficiency contributes to hepatocellular carcinoma tumorigenesis.
ARID1A positively regulates Klf15 expression with PGR (show PGR Antibodies) to inhibit epithelial proliferation at peri (show POSTN Antibodies)-implantation. Our results suggest that Arid1a has a critical role in modulating epithelial proliferation which is a critical requisite for fertility
This gene encodes a protein involved in the sodium-independent transport and excretion of organic anions, some of which are potentially toxic. The encoded protein is an integral membrane protein and appears to be localized to the basolateral membrane of the kidney. Multiple alternatively spliced transcript variants that encode different protein isoforms have been described for this gene.
ARID domain-containing protein 1A
, AT-rich interactive domain-containing protein 1A
, BRG1-associated factor 250a
, OSA1 nuclear protein
, SWI-like protein
, SWI/SNF complex protein p270
, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily F member 1
, brain protein 120
, chromatin remodeling factor p250
, osa homolog 1
, organic anion transporter 3
, solute carrier family 22 member 8
, AT rich interactive domain 1A (Swi1 like)
, BRG1-associated factor 250
, SWI-SNF complex protein p270
, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily f, member 1
, Swi1 like
, AT rich interactive domain 1A (SWI-like)
, AT-rich interactive domain-containing protein 1A-like
, AT rich interactive domain 1Aa (SWI-like)